There is no doubt that Dr Chava had been painting a very optimistic picture and downplaying the risks, for last few quarters. However if one looks at the company and its very humble beginnings, the thesis survives. These kind of first gen entrepreneurs are a hardy and smart lot and very capable of overcoming major and minor setbacks. Laurus became complacent and thought that they could dictate the market for ARV formulations and discovered to the contrary with a learning fee of 500 crores. So a much more modest Dr Chava states that he has changed his strategy ie he will now follow the market. Therefore I will stay.
| Subscribe To Our Free Newsletter |
